Website
News25/Ratings12
News · 26 weeks66+33%
2025-10-262026-04-19
Mix3790d
- SEC Filings24(65%)
- Other7(19%)
- Analyst5(14%)
- Earnings1(3%)
Latest news
25 items- ANALYSTGenmab upgraded by GoldmanGoldman upgraded Genmab from Neutral to Buy
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,114,318 shares in Genmab A/S, which amounts to 4.85% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world. Genmab receives royalties on the wo
- PRGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian CancerPhase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3 RAINFOL-04 trial will further evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC) Genmab A/S (NASDAQ:GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety pr
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 27, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,205,763 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people
- ANALYSTWolfe Research initiated coverage on Genmab with a new price targetWolfe Research initiated coverage of Genmab with a rating of Outperform and set a new price target of $32.00
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- ANALYSTWells Fargo initiated coverage on Genmab with a new price targetWells Fargo initiated coverage of Genmab with a rating of Overweight and set a new price target of $40.00
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)